(Q53615730)

16 May 2018

title

A phase I surrogate endpoint study of SU6668 in patients with solid tumors. (English)

1 reference

16 May 2018

author

Edward F. Jackson

6

1 reference

16 May 2018

Roy S. Herbst

2

object named as

Roy Herbst

1 reference

16 May 2018

author name string

Henry Q Xiong

1

1 reference

16 May 2018

Silvana C Faria

3

1 reference

16 May 2018

Catherine Scholz

4

1 reference

16 May 2018

Darren Davis

5

1 reference

16 May 2018

Timothy Madden

7

1 reference

16 May 2018

David McConkey

8

1 reference

16 May 2018

Marshall Hicks

9

1 reference

16 May 2018

Kenneth Hess

10

1 reference

16 May 2018

Chusilp Arthur Charnsangavej

11

1 reference

16 May 2018

James L Abbruzzese

12

1 reference

16 May 2018

publication date

1 November 2004

1 reference

16 May 2018

Investigational New Drugs

published in

1 reference

16 May 2018

volume

22

1 reference

16 May 2018

issue

4

1 reference

16 May 2018

page(s)

459-466

1 reference

16 May 2018

https://scigraph.springernature.com/pub.10.1023/b:drug.0000036688.96453.8d

exact match

0 references

cites work

Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms

1 reference

12 December 2020

Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer

1 reference

12 December 2020

Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis

1 reference

12 December 2020

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

12 December 2020

Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer

1 reference

12 December 2020

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

1 reference

12 December 2020

Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma

1 reference

12 December 2020

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.

1 reference

12 December 2020

Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.

1 reference

12 December 2020

Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth

1 reference

12 December 2020

Surrogate markers in antiangiogenesis clinical trials

1 reference

12 December 2020

The biology of vascular endothelial growth factor

1 reference

12 December 2020

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract

1 reference

12 December 2020

Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer

1 reference

12 December 2020

Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival

1 reference

12 December 2020

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

12 December 2020

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

12 December 2020

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

12 December 2020

Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies

1 reference

12 December 2020

Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells

1 reference

12 December 2020

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

12 December 2020

SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

1 reference

12 December 2020

10.1023/B:DRUG.0000036688.96453.8D

Identifiers

DOI

1 reference

16 May 2018

Dimensions Publication ID

0 references

1 reference

16 May 2018